RESprotect Overview

  • Founded
  • 2000
  • Status
  • Private
  • Employees
  • 5
  • Latest Deal Type
  • 2ndary - Private
  • Latest Deal Amount
  • $1M
Latest Deal Amount
  • Investors
  • 3

RESprotect General Information


Developer of drugs intended for prevention and treatment of chemotherapeutic drug resistance and radiation therapy resistance. The company's small molecule drugs contain products such as Hsp27, RP101 which are given orally to cancer patients in combination with standard of care chemotherapy, enabling pancreatic cancer patients to kill tumor cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
  • Krippener Street 18b
  • 01259 Dresden
  • Germany
+49 0351 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

RESprotect Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 15-Apr-2009 $1M 00.000 0000 Completed Startup
1. Early Stage VC 30-Aug-2000 00.000 00.000 Completed Startup
To view RESprotect’s complete valuation and funding history, request access »

RESprotect Executive Team (5)

Name Title Board Seat Contact Info
Rudolf Fahrig Founder, Chief Executive Officer & Managing Director
Torsten Fahrig Ph.D Chief Operating Officer & Chief Financial Officer
Jörg-Christian Heinrich Chief Scientific Officer & Director, Research of Cell and Molecular Biology
Andreas Koch Ph.D Director, Chemistry and Pharmacy
Klaus Kutz MD Chief Medical Officer, Clinical Studies
To view RESprotect’s complete executive team members history, request access »

RESprotect Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RESprotect Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Avantogen Corporation Minority 000 0000 000000 0
CFH Management PE/Buyout Minority 000 0000 000000 0
Fraunhofer Venture Corporate Venture Capital Minority 000 0000 000000 0
To view RESprotect’s complete investors history, request access »